JP2022547401A5 - - Google Patents

Info

Publication number
JP2022547401A5
JP2022547401A5 JP2022507861A JP2022507861A JP2022547401A5 JP 2022547401 A5 JP2022547401 A5 JP 2022547401A5 JP 2022507861 A JP2022507861 A JP 2022507861A JP 2022507861 A JP2022507861 A JP 2022507861A JP 2022547401 A5 JP2022547401 A5 JP 2022547401A5
Authority
JP
Japan
Prior art keywords
patient
eye
affected
symptoms
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022507861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547401A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050150 external-priority patent/WO2021050692A2/en
Publication of JP2022547401A publication Critical patent/JP2022547401A/ja
Publication of JP2022547401A5 publication Critical patent/JP2022547401A5/ja
Pending legal-status Critical Current

Links

JP2022507861A 2019-09-10 2020-09-10 翼状片に関連した眼の見た目についての心配を軽減するための方法 Pending JP2022547401A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962898401P 2019-09-10 2019-09-10
US62/898,401 2019-09-10
PCT/US2020/050150 WO2021050692A2 (en) 2019-09-10 2020-09-10 Methods for alleviating pterygium-associated worry about eye appearance

Publications (2)

Publication Number Publication Date
JP2022547401A JP2022547401A (ja) 2022-11-14
JP2022547401A5 true JP2022547401A5 (OSRAM) 2023-09-19

Family

ID=74870040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022507861A Pending JP2022547401A (ja) 2019-09-10 2020-09-10 翼状片に関連した眼の見た目についての心配を軽減するための方法

Country Status (10)

Country Link
US (1) US20220331310A1 (OSRAM)
EP (1) EP4027997A4 (OSRAM)
JP (1) JP2022547401A (OSRAM)
KR (1) KR20220061147A (OSRAM)
CN (1) CN114340618A (OSRAM)
AU (2) AU2020346812A1 (OSRAM)
BR (1) BR112021026662A2 (OSRAM)
CA (1) CA3146811A1 (OSRAM)
MX (1) MX2022000468A (OSRAM)
WO (1) WO2021050692A2 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2971096T3 (es) 2015-06-06 2024-06-03 Cloudbreak Therapeutics Llc Composiciones y métodos para tratar el terigio
CA3026118A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100185564A1 (en) * 2009-01-21 2010-07-22 Mccormick & Company, Inc. Method and questionnaire for measuring consumer emotions associated with products
CA2877710A1 (en) * 2012-06-25 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing pazopanib
US8747852B1 (en) * 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
ES2971096T3 (es) * 2015-06-06 2024-06-03 Cloudbreak Therapeutics Llc Composiciones y métodos para tratar el terigio
CR20170566A (es) * 2015-06-09 2018-03-20 Bayer Pharma AG Moduladores alostéricos positivos del receptor muscarínico m2
TWI664965B (zh) * 2015-06-22 2019-07-11 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法
CN108295072A (zh) * 2015-12-09 2018-07-20 瑞阳(苏州)生物科技有限公司 尼达尼布防治眼部疾病的用途
CA3010623A1 (en) * 2016-02-04 2017-08-10 Jinsong Ni Antibody-drug synergism technology for treating diseases
CA3026118A1 (en) * 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
US11278546B2 (en) * 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
MX2019003623A (es) * 2016-09-28 2019-09-23 Medicon Pharmaceuticals Inc Composiciones y metodos para el tratamiento de afecciones oftalmicas.
CN116063221A (zh) * 2017-03-14 2023-05-05 新源生物科技股份有限公司 尼达尼布的晶型
CN112165934A (zh) * 2018-05-25 2021-01-01 克劳德布雷克医疗有限责任公司 治疗眼充血的组合物及用其治疗眼充血的方法

Similar Documents

Publication Publication Date Title
RU2731000C2 (ru) Нейроактивные стероиды, композиции и способы их применения
JP2021130687A (ja) ガボキサドールでの発達障害の処置方法
CA3158448A1 (en) Neuroactive steroids, compositions, and uses thereof
US20140249166A1 (en) Methods of treating patients suffering from movement disorders
TW200402296A (en) Combination of brimonidine and timolol for topical ophthalmic use
JPH045648B2 (OSRAM)
US11723890B2 (en) Methods of treatment using an mTORC1 modulator
JP2019535760A (ja) フルピルチンを用いた発達障害および／または発作性障害の処置方法
TW202112377A (zh) 藉由jak抑制劑局部治療白斑症
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
JP2022545568A5 (OSRAM)
JP2002509104A (ja) 遅発性ジスキネジア及び他の運動障害の治療方法
WO2020198039A1 (en) Ketamine for treatment of sensory processing deficits
AU2026202351A1 (en) Methods for alleviating pterygium-associated worry about eye appearance
JP2022514659A (ja) ドーパミン作動性ｃｎｓ障害の治療におけるｌｙ３１５４２０７の使用のための用量レジメン
Hass et al. Comparison between pilocarpine and timolol on diurnal pressures in open-angle glaucoma
JPH09278653A (ja) 網膜疾患治療剤
RS60365B1 (sr) Lečenje alopecije areate
US20240408086A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
CN115634226A (zh) 一种采用长春西汀治疗近视的方法
RU2469734C2 (ru) Лечебное средство для лечения расстройств аккомодаций "stiak"
JP4234218B2 (ja) 特定の神経運動障害および精神−知力障害の処置に有用な医薬組成物を得るためのスルブチアミンの用途
WO1995028934A2 (en) Use of mao-a inhibitors for the manufacture of a medicament in the treatment of tobacco withdrawal symptoms in smokers
WO2025188619A1 (en) Methods of treating parkinson's disease with t-type calcium channel modulators
JP2020517681A (ja) 中枢神経系の変性疾患及び／又はリソソーム蓄積疾患を予防及び／又は治療するための新規組成物